dolasetron has been researched along with Benign Neoplasms in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (51.85) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 2 (7.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballinari, G; Barbour, SY; Cox, D; Morrow, GR; Schwartzberg, L; Thorn, MD | 1 |
| Boušová, I; Matoušková, P; Skálová, L; Souček, P | 1 |
| Cartmell, A; Charu, V; Eisenberg, P; Figueroa-Vadillo, J; Grunberg, S; Hajdenberg, J; Macciocchi, A; Zamora, R | 1 |
| Seth, R; Tan, M; Xu, R | 1 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| McNulty, R | 1 |
| Wilkes, G | 1 |
| Awan, FT; Chaudhary, L; Hamadani, M; Khan, JK; Kojouri, K; Ozer, H; Tfayli, A | 1 |
| Catimel, G; Clavel, M; Dumortier, A; Guastalla, JP; Merrouche, Y; O'Grady, P; Rebattu, P | 1 |
| Cappelaere, P; Chauvergne, J; Chevallier, B; Conroy, T; Fabbro, M; Fauser, AA; Goupil, A; Schneider, M; Spielmann, M; Splinter, TA | 1 |
| Aapro, M; Alberto, P; Boyce, M; Busch, B; Kirchner, V; O'Grady, P | 1 |
| Cramer, MB; Facada, A; Gandara, DR; Hahne, WF; Hesketh, AM; Hesketh, PJ; Martin, LA; Perez, EA; Webber, LM | 1 |
| Anthony, L; Benedict, C; Gralla, R; Grote, T; Hahne, W; Hainsworth, J; Hesketh, P; Khojasteh, A; Kris, M; Navari, R; Tapazoglou, E | 1 |
| Brawley, OW; Cheson, BD; Phillips, PH | 1 |
| Bey, P; Bourdin, S; Claverie, N; Hahne, W; Le Floch, O; Resbeut, M; Wilkinson, PM | 1 |
| Chemaissani, A; Cognetti, F; Conte, PF; Cortes-Funes, H; Del Favero, A; Diaz-Rubio, E; Dressler, H; Duclos, B; Fauser, AA | 1 |
| Bastit, P; Cals, L; Cappelaere, P; Catimel, G; Chevallier, B; Claverie, N; Fabbro, M; Giovannini, M; Khayat, D; Splinter, T; Wendling, JL | 1 |
| Allman, DS; Baker, TW; Chernoff, SB; Ferguson, BB; Fernando, IJ; Grote, TH; Kris, MG; Navari, RM; Nelson, AM; Pendergrass, KB; Pizzo, BA; Thomas, V | 1 |
| Cramer, MB; DuBois, DM; Grote, TH; Hahne, WF; Hesketh, PJ; Kris, MG; Whitmore, JB | 1 |
| Barr, R; Coppes, MJ; Dempsey, E; Grant, R; Greenberg, ML; Howard, DR; Ingram, LC; Lau, R; Leclerc, JM; Perrotta, M; Wiernikowski, JT | 1 |
| Cramer, MB; Dimmitt, DC; Hahne, WF; Lippert, CL; Martin, L; Plezia, P | 1 |
| Fauser, AA; Khayat, D; Pizzocaro, G; Schueller, J; Wilkinson, P | 1 |
| Eremita, D | 1 |
| Keefe, DL | 1 |
6 review(s) available for dolasetron and Benign Neoplasms
| Article | Year |
|---|---|
The modulation of carbonyl reductase 1 by polyphenols.
Topics: Alcohol Oxidoreductases; Animals; Bupropion; Butanones; Butyrophenones; Daunorubicin; Doxorubicin; Gene Expression Regulation, Enzymologic; Haloperidol; Humans; Indoles; Nabumetone; Neoplasms; Phenylpropionates; Polyphenols; Quinolizines; Substrate Specificity; Xenobiotics | 2015 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Dexamethasone; Female; Half-Life; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Protein Binding; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Neoplasms; Ondansetron; Palonosetron; Patient Satisfaction; Prognosis; Quality of Life; Quinolizines; Quinuclidines; Treatment Outcome; Tropisetron; Vomiting | 2005 |
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Vomiting | 1998 |
Dolasetron for chemo nausea.
Topics: Antiemetics; Antineoplastic Agents; Humans; Indoles; Nausea; Neoplasms; Quinolizines | 2001 |
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Electrocardiography; Granisetron; Heart Failure; Humans; Indoles; Middle Aged; Nausea; Neoplasms; Ondansetron; Quinolizines; Serotonin Antagonists; Vomiting | 2002 |
14 trial(s) available for dolasetron and Benign Neoplasms
| Article | Year |
|---|---|
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinolizines; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2003 |
Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
Topics: Antiemetics; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; United States; Vomiting | 2004 |
A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Diarrhea; Female; Headache; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1994 |
Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Constipation; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1993 |
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Indoles; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Pilot Projects; Quinolizines; Vomiting | 1996 |
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis P
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Quinolizines; Remission Induction; Serotonin Antagonists; United States; Vomiting | 1996 |
A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Double-Blind Method; Female; Humans; Indoles; Injections, Intravenous; Linear Models; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Radiotherapy, High-Energy; Treatment Outcome; Vomiting | 1996 |
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; Indoles; Logistic Models; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Patient Satisfaction; Quinolizines; Risk Factors; Therapeutic Equivalency; Vomiting | 1996 |
A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
Topics: Acute Disease; Alcoholism; Antiemetics; Antineoplastic Agents; Basal Ganglia Diseases; Cisplatin; Double-Blind Method; Female; Headache; Humans; Indoles; Injections, Intravenous; Male; Metoclopramide; Middle Aged; Nausea; Neoplasms; Patient Satisfaction; Quinolizines; Remission Induction; Safety; Serotonin Antagonists; Sex Factors; Vomiting | 1997 |
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Topics: Acute Disease; Administration, Oral; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Vomiting | 1997 |
Open-label comparison of the antiemetic efficacy of single intravenous doses of dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Area Under Curve; Child; Child, Preschool; Female; Humans; Indoles; Infusions, Intravenous; Male; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1999 |
Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Quinolizines; Serotonin Antagonists; Time Factors | 1999 |
A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
Topics: Adult; Analysis of Variance; Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Logistic Models; Male; Middle Aged; Nausea; Neoplasms; Patient Satisfaction; Quinolizines; Statistics, Nonparametric; Treatment Outcome; Vomiting | 2000 |
7 other study(ies) available for dolasetron and Benign Neoplasms
| Article | Year |
|---|---|
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron; Vomiting | 2005 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Therapeutic Equivalency; Vomiting | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Granisetron; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Platinum Compounds; Quinolizines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2007 |
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Indoles; Male; Middle Aged; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Treatment Outcome; Vomiting | 1994 |
Clinical trials referral resource. Cancer chemoprevention and control trials.
Topics: Analgesics; Anorexia; Antiemetics; Antineoplastic Agents; Behavior Therapy; Cachexia; Cisplatin; Clinical Trials as Topic; Dexamethasone; Drug Combinations; Humans; Indoles; Megestrol; Megestrol Acetate; Neoplasms; Pain, Intractable; Pilot Projects; Quinolizines; Vomiting; Vomiting, Anticipatory | 1996 |
Dolasetron for prevention of nausea and vomiting due to cancer chemotherapy.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Nausea; Neoplasms; Quinolizines; Serotonin Antagonists; Vomiting | 1998 |